• Merck & Co. Inc., of Whitehouse Station, N.J., presented results from a Phase Ib study of MK-8931 in Alzheimer's disease at the Alzheimer's Association International Conference in Boston, showing a dose-dependent decrease in beta amyloid levels in cerebral spinal fluid following administration of the drug in patients with mild to moderate disease.